50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

Key Takeaways Explain This Topic AI

Heart failure is categorized by left ventricular ejection fraction into HFrEF (LVEF <=40%), HFmrEF (LVEF 41-49%), and HFpEF (LVEF >=50%), staged longitudinally from Stage A (at risk) to Stage D (advanced/refractory), with functional severity quantified by NYHA Classes I through IV.

Quadruple Guideline-Directed Medical Therapy (GDMT) for HFrEF comprises four foundational pillars that collectively reduce all-cause mortality by >60%: 1) ARNI (sacubitril/valsartan preferred over ACEi/ARB), 2) an evidence-based beta-blocker (only metoprolol succinate ER, carvedilol, or bisoprolol), 3) a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and 4) an SGLT2 inhibitor (dapagliflozin or empagliflozin, effective regardless of diabetes status).

A mandatory 36-hour washout period is strictly required when transitioning a patient from an ACE inhibitor to Sacubitril/Valsartan to avoid dual neprilysin/ACE inhibition of bradykinin degradation and catastrophic, life-threatening angioedema; no washout is required when switching from an ARB.

Implantable Cardioverter-Defibrillator (ICD) therapy is indicated for primary prevention of sudden cardiac death in ischemic cardiomyopathy (>=40 days post-MI) or non-ischemic cardiomyopathy with LVEF <=35% and NYHA Class II-III on >=3 months of optimal GDMT; Cardiac Resynchronization Therapy (CRT) is indicated for LVEF <=35%, sinus rhythm, LBBB with QRS >=150 ms, and NYHA Class II-IV symptoms.

In HFpEF (LVEF >=50%), SGLT2 inhibitors (empagliflozin or dapagliflozin) are the first and only drug class with Class 1 guideline recommendations proven in landmark randomized trials (EMPEROR-Preserved, DELIVER) to significantly reduce the composite risk of cardiovascular death and heart failure hospitalizations.

Last updated: September 2026

Classification, Phenotypes & Staging of Heart Failure

Heart failure (HF) is a complex clinical syndrome resulting from any structural or functional impairment of ventricular filling or ejection of blood. Cardinal manifestations include dyspnea, fatigue, exercise intolerance, and signs of fluid retention (pulmonary crackles, elevated jugular venous pressure, peripheral edema).

Heart Failure Phenotypes by Ejection Fraction

The 2022 ACC/AHA/HFSA guidelines classify heart failure into distinct phenotypes based on left ventricular ejection fraction (LVEF), which fundamentally guides clinical prognosis and evidence-based pharmacotherapy: HEART FAILURE PHENOTYPIC CLASSIFICATION

Phenotype LVEF Cutoff Cardinal Pathophysiology & Structural Features
═════════════════════════════════════════════════════════════════════════════════════════
Heart Failure with LVEF <= 40% Primary systolic contractile failure; progressive
Reduced EF (HFrEF) ventricular dilation; eccentric hypertrophy; massive

neurohormonal activation (RAAS, sympathetic nervous system).

Heart Failure with LVEF 41% to 49% Intermediate demographic and clinical profile;
Mildly Reduced EF substantial biological overlap with HFrEF; post-hoc trial

(HFmrEF) analyses prove significant benefit from HFrEF GDMT.

Heart Failure with LVEF >= 50% Primary diastolic relaxation impairment; increased chamber
Preserved EF (HFpEF) stiffness; concentric LV hypertrophy; elevated LV filling

pressures (LVEDP and PCWP); microvascular inflammation.

Heart Failure with Previous LVEF Subgroup of HFrEF patients who demonstrate significant
Improved EF (HFimpEF) <=40% with structural recovery and LVEF increase >40% on GDMT;

follow-up >40% MANDATORY RULE: Continue full GDMT indefinitely (do NOT stop!).

═════════════════════════════════════════════════════════════════════════════════════════

The Diagnostic Framework for HFpEF: The H2FPEF Score :

Diagnosing HFpEF is notoriously challenging because resting echocardiography may reveal a normal LVEF and non-dilated ventricles.

The validated H2FPEF Score calculates clinical probability based on 6 weighted clinical variables:

H : Heavy (Body Mass Index >30 kg/m²) = 2 points ;
H : Hypertensive (requiring >=2 antihypertensive medications) = 1 point ;
F : Atrial Fibrillation (paroxysmal or persistent) = 3 points ;
P : Pulmonary Hypertension (pulmonary artery systolic pressure >35 mmHg on echo) = 1 point ;
E : Elder (age >60 years) = 1 point ;

F : Filling Pressures Elevated (echocardiographic early mitral inflow-to-annular tissue velocity ratio, E / e ′ > 9 E/e' > 9 E / e ′ > 9 ) = 1 point .

An H2FPEF score >=6 points confirms the diagnosis of HFpEF with >90% probability.

Longitudinal Staging (ACC/AHA) vs. Functional Severity (NYHA)

Heart failure is categorized using two complementary classification systems: the progressive ACC/AHA Stages (A through D) and the dynamic, symptom-driven New York Heart Association (NYHA) Functional Classes (I through IV) . ACC/AHA STAGES VS. NYHA FUNCTIONAL CLASSIFICATION

ACC/AHA Stage (Longitudinal Progression) NYHA Functional Class (Subjective Symptoms)
═════════════════════════════════════════════════════════════════════════════════════════
Stage A: At Risk for Heart Failure (No NYHA equivalent: asymptomatic)
Patients with risk factors (HTN, diabetes,
ASCVD, obesity, cardiotoxins) WITHOUT

structural disease or symptoms.

Stage B: Pre-Heart Failure NYHA Class I: No Limitation
Patients with structural heart disease (LVH, Ordinary physical activity does not cause undue

LVEF <=40%, chamber enlargement, prior MI) fatigue, palpitation, or dyspnea.

OR elevated cardiac biomarkers (BNP/troponin)

WITHOUT past or present HF symptoms.

Stage C: Symptomatic Heart Failure NYHA Class II: Slight Limitation
Structural heart disease WITH past or Comfortable at rest; ordinary activity causes

current signs/symptoms of heart failure. fatigue, palpitation, or dyspnea.

NYHA Class III: Marked Limitation
Comfortable at rest; LESS THAN ordinary

activity causes fatigue or dyspnea.

Stage D: Advanced / Refractory HF NYHA Class IV: Severe Symptoms at Rest
End-stage structural heart disease with Inability to perform any physical activity without
severe refractory symptoms at rest despite discomfort; symptoms present even at complete rest;

maximal GDMT; requires specialized advanced frequent hospitalizations; bedbound.

therapies (inotropes, LVAD, transplant, hospice).

═════════════════════════════════════════════════════════════════════════════════════════

The "Four Pillars" of Quadruple GDMT in HFrEF

In patients with symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF: Stage C, LVEF <=40%), contemporary guideline consensus establishes Quadruple Guideline-Directed Medical Therapy (GDMT) . Initiating and titrating all four foundational drug classes simultaneously reduces all-cause mortality, cardiovascular death, and heart failure hospitalizations by over 60% compared to historical standards. THE FOUR PILLARS OF QUADRUPLE GDMT FOR HFREF

Pillar & Class Target Agents & Dosing Mechanisms & Trial Evidence
═════════════════════════════════════════════════════════════════════════════════════════════════════════════
1. ARNI Sacubitril / Valsartan Inhibits neprilysin (enhances natriuretic
(Preferred over (Initial: 24/26 mg or 49/51 mg BID; peptides) + blocks AT1 receptor;

ACEi / ARB) Target: 97/103 mg twice daily) PARADIGM-HF: 20% reduction in CV death/HF hosp.

MANDATORY 36-HOUR WASHOUT from ACEi!

2. Evidence-Based ONLY THREE APPROVED AGENTS: Competitively blocks adrenergic cardiotoxicity,
Beta-Blockers • Metoprolol succinate ER (target 200 mg qd) reduces arrhythmias, reverses LV remodeling;

Carvedilol (target 25-50 mg BID) MERIT-HF, COPERNICUS, CIBIS-II trials:
Bisoprolol (target 10 mg daily) ~35% reduction in all-cause mortality.

3. Mineralocorticoid Spironolactone (12.5-25 mg; target 50 mg qd) Blocks aldosterone binding in myocardium/kidney;

Receptor OR Eplerenone (25 mg; target 50 mg qd) anti-fibrotic; reduces sudden cardiac death;

Antagonist (MRA) RALES, EMPHASIS-HF: 30% mortality reduction.

4. SGLT2 Inhibitor Dapagliflozin 10 mg daily Promotes osmotic natriuresis, reduces preload/
OR Empagliflozin 10 mg daily afterload, improves myocardial energetics;
DAPA-HF, EMPEROR-Reduced: 25% CV death/hosp drop;

PROVEN EFFECTIVE IN DIABETICS & NON-DIABETICS!

═════════════════════════════════════════════════════════════════════════════════════════════════════════════
Critical Pharmacologic & Safety Rules for the Four Pillars

ARNI (Sacubitril/Valsartan) & The 36-Hour Washout Rule :

Mechanism : Sacubitril is a prodrug that inhibits neprilysin (neutral endopeptidase), the primary enzymatic pathway degrading endogenous vasoactive natriuretic peptides (ANP, BNP, CNP), bradykinin, and adrenomedullin. Accumulation of natriuretic peptides promotes diuresis, natriuresis, vasodilation, and reverse remodeling. Valsartan selectively blocks angiotensin II AT1 receptors.

PARADIGM-HF Trial : Proved Sacubitril/Valsartan is significantly superior to enalapril 10 mg BID, producing a 20% reduction in cardiovascular death and a 21% reduction in heart failure hospitalizations. ARNI is the preferred first-line agent over ACEi or ARB for all symptomatic HFrEF patients.

Caution

THE CRITICAL SAFETY MANDATE: 36-HOUR WASHOUT PERIOD When switching a patient from an ACE inhibitor (e.g., lisinopril, enalapril) to Sacubitril/Valsartan, the clinician must enforce a MANDATORY 36-HOUR WASHOUT PERIOD between the last dose of the ACE inhibitor and the first dose of Sacubitril/Valsartan.

Both ACE and neprilysin degrade bradykinin . Concurrent inhibition of both enzymes leads to massive, unchecked bradykinin accumulation, precipitating catastrophic, life-threatening angioedema with acute airway obstruction .

When switching from an ARB to Sacubitril/Valsartan, NO WASHOUT PERIOD IS REQUIRED (because ARBs do not inhibit bradykinin degradation).

Biomarker Monitoring Pearl : Because neprilysin degrades BNP, administration of Sacubitril/Valsartan causes a pharmacologic rise in circulating BNP . Therefore, serum BNP levels are falsely elevated and cannot be used to assess decompensation. Clinicians must measure N-terminal pro-B-type natriuretic peptide (NT-proBNP) , which is not a substrate for neprilysin and accurately reflects myocardial wall stress.

Evidence-Based Beta-Blockers: Only Three Approved Agents :

Only three specific beta-blockers are supported by robust clinical trial evidence demonstrating significant reductions in all-cause mortality in HFrEF:

Metoprolol succinate extended-release (MERIT-HF trial; target 200 mg once daily);

Carvedilol (non-selective beta and alpha-1 blocker; COPERNICUS and CAPRICORN trials; target 25 to 50 mg twice daily);

Bisoprolol (selective beta-1 blocker; CIBIS-II trial; target 10 mg once daily).

Agents Strictly Ineffective / Avoided in HFrEF : Metoprolol tartrate (short-acting; the COMET trial proved metoprolol tartrate is markedly inferior to carvedilol and failed to improve survival), atenolol , and propranolol are NOT approved for HFrEF and must never be prescribed for this indication.

Initiation Protocol : Beta-blockers must be initiated only in clinically stable, euvolemic patients (no active fluid overload or worsening decompensation). "Start low and go slow," titrating upward every 2 to 4 weeks toward target trial doses.

Mineralocorticoid Receptor Antagonists (MRAs) :

Spironolactone (12.5 to 25 mg daily) or Eplerenone (25 to 50 mg daily; selective MRA avoiding gynecomastia).

Indicated in all symptomatic HFrEF patients with LVEF <=35% (NYHA Class II-IV).

Prerequisites & Safety Thresholds : Baseline serum potassium must be <=5.0 mEq/L and eGFR must be >=30 mL/min/1.73m² (or serum creatinine <=2.5 mg/dL in men, <=2.0 mg/dL in women). Monitor electrolytes and renal function at 1 week, 4 weeks, and every 3 to 6 months. Hold or discontinue if serum potassium exceeds 5.5 mEq/L.

SGLT2 Inhibitors (Dapagliflozin & Empagliflozin) :

Dapagliflozin (10 mg daily) and Empagliflozin (10 mg daily) represent the fourth pillar of GDMT.

The landmark DAPA-HF and EMPEROR-Reduced trials demonstrated a profound 25% to 30% reduction in cardiovascular death and heart failure hospitalization.

Important

THE UNIVERSAL SGLT2i PEARL: INDEPENDENT OF DIABETES The survival and hospitalization benefits of SGLT2 inhibitors in HFrEF are IDENTICAL IN PATIENTS WITH AND WITHOUT TYPE 2 DIABETES MELLITUS .

In non-diabetic heart failure patients, SGLT2 inhibitors do not cause hypoglycemia. They function as neurohormonal modifiers that reduce intracardiac filling pressures, enhance myocardial energetics, promote osmotic natriuresis, and prevent chronic renal decline.

Decongestion, Second-Line Therapies & Device Interventions
Decongestion: Loop Diuretic Titration

Loop diuretics (furosemide, bumetanide, torsemide) act on the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle .

Role in GDMT : Loop diuretics do NOT reduce mortality in HFrEF; their sole clinical purpose is to restore and maintain euvolemia by eliminating peripheral edema, ascites, and pulmonary venous congestion.

Bioavailability & Conversions :

Oral furosemide has poor and highly erratic oral bioavailability (~50%, varying from 10% to 90%), which is severely impaired by gut wall edema in decompensated heart failure. In acute decompensation, IV furosemide is approximately twice as potent as oral furosemide ( 40 mg oral = 20 mg IV ).

Torsemide (80-100% bioavailability) and Bumetanide (80-100% bioavailability) exhibit highly predictable oral absorption unaffected by bowel edema.

Dose Equivalence : Oral Furosemide 40 mg = IV Furosemide 20 mg = Oral Torsemide 20 mg = Oral Bumetanide 1 mg.

Diuretic Resistance : Managed by escalating loop diuretic doses, switching from oral furosemide to torsemide/bumetanide, or administering sequential nephron blockade by adding a thiazide diuretic ( metolazone 2.5 to 5 mg PO or IV chlorothiazide) 30 minutes prior to the loop diuretic dose.

Phenotype-Specific Second-Line Therapies

Hydralazine plus Isosorbide Dinitrate (BiDil) :

The A-HeFT trial demonstrated that the fixed-dose combination of hydralazine (direct arteriolar vasodilator) plus isosorbide dinitrate (venodilator) produced a 43% reduction in mortality and a 33% reduction in HF hospitalizations when added to standard therapy in self-identified Black patients with persistent NYHA Class III-IV symptoms .

Indicated in self-identified Black patients with persistent symptoms despite optimal quadruple GDMT, OR in any patient intolerant to ARNI/ACEi/ARB due to severe renal insufficiency or intractable hyperkalemia.

Ivabradine :

Selectively inhibits the hyperpolarization-activated cyclic nucleotide-gated ( I f I_f I f ) funny current in the sinoatrial node, slowing sinus rate without affecting inotropy, ventricular repolarization, or blood pressure.

Indicated in patients with symptomatic HFrEF (LVEF <=35%), in normal sinus rhythm with a resting heart rate >=70 bpm , who are already receiving maximally tolerated doses of an evidence-based beta-blocker (or have a documented contraindication to beta-blockers).

Vericiguat :

An oral stimulator of soluble guanylate cyclase (sGC) , directly enhancing the cyclic GMP pathway in smooth muscle and myocardium.

Indicated in high-risk HFrEF patients with a recent worsening heart failure hospitalization or outpatient IV diuretic requirement despite optimal GDMT (VICTORIA trial).

Device Therapy: Primary Prevention ICD & CRT

Sudden cardiac death from ventricular tachycardia or ventricular fibrillation accounts for up to 50% of deaths in HFrEF. Device therapy indications are strictly guided by LVEF, etiology, and QRS morphology: DEVICE THERAPY INDICATIONS IN HFREF

Device Modality Guideline Indications & Selection Criteria
═════════════════════════════════════════════════════════════════════════════════════════

Implantable PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH:

Cardioverter- 1. Ischemic Cardiomyopathy: LVEF <= 35%, NYHA Class II or III,
Defibrillator (ICD) at least >= 40 DAYS post-myocardial infarction, AND on >= 3 months

of optimal guideline-directed medical therapy.

2. Non-Ischemic Dilated Cardiomyopathy: LVEF <= 35%, NYHA Class II or III,

on >= 3 months of optimal guideline-directed medical therapy.

*Exclusions: NYHA Class IV refractory symptoms (unless awaiting LVAD/transplant);

life expectancy < 1 year.

Cardiac BIVENTRICULAR PACING FOR MECHANICAL DYSSYNCHRONY:

Resynchronization 1. LVEF <= 35% on optimal GDMT;
Therapy (CRT / CRT-D) 2. Normal Sinus Rhythm;
3. Left Bundle Branch Block (LBBB) with QRS duration >= 150 ms (Class 1)
(or LBBB with QRS 120-149 ms, or non-LBBB with QRS >=150 ms [Class 2a]);

4. Symptomatic NYHA Class II, III, or ambulatory Class IV.

═════════════════════════════════════════════════════════════════════════════════════════
Contemporary Management of HFpEF (LVEF >=50%)

Historically, clinical trials of ACE inhibitors, ARBs, and beta-blockers in HFpEF failed to demonstrate mortality benefits. However, groundbreaking recent trials have revolutionized the therapeutic paradigm:

SGLT2 Inhibitors: The Landmark Class 1 GDMT :

Empagliflozin (EMPEROR-Preserved trial) and Dapagliflozin (DELIVER trial) are the first and only medications proven to significantly reduce the composite risk of cardiovascular death and heart failure hospitalizations across the entire spectrum of HFpEF .

SGLT2 inhibitors now carry a Class 1 guideline recommendation for all patients with HFpEF regardless of diabetes status.

Mineralocorticoid Receptor Antagonists (MRAs) :

In the TOPCAT trial, spironolactone significantly reduced heart failure hospitalizations in patients with elevated natriuretic peptides, carrying a Class 2b recommendation in HFpEF.

ARNI (Sacubitril/Valsartan) :

In the PARAGON-HF trial, sacubitril/valsartan demonstrated a reduction in heart failure hospitalizations, with greatest efficacy observed in patients with LVEF on the lower end of the preserved spectrum (LVEF 50% to 57%) and in women (Class 2b recommendation).

Loop Diuretics & Aggressive Comorbidity Control :

Titrate loop diuretics to relieve systemic and pulmonary venous congestion (edema, elevated jugular venous distention, dyspnea).

Rigorously manage contributing comorbidities: strict blood pressure control (<130/80 mmHg), rate or rhythm control in atrial fibrillation, continuous positive airway pressure (CPAP) for obstructive sleep apnea, and structured weight loss.